Last updated: March 1, 2026
What is NDC 78206-0173?
NDC 78206-0173 corresponds to a branded drug product approved by the FDA, with specific formulation, strength, and packaging. The product is indicated for a particular therapeutic use, typically in the area of oncology, endocrinology, or cardiovascular health. Specific data on the drug’s chemical composition, dosage form, and approved indications are essential to evaluate its market potential.
Market Landscape
Therapeutic Area and Competitive Environment
The drug operates within a high-growth therapeutic segment, such as oncology or autoimmune diseases, with the following characteristics:
- Market Size: Estimated global revenue for the relevant therapeutic class reached $X billion in 2022, with an annual growth rate of approximately X%.
- Key Competitors: Includes drugs A, B, and C, capturing X%, Y%, and Z% of the market share, respectively.
- Market Trends: Increasing adoption of targeted therapies, rising prevalence of indications, and expansion into emerging markets drive growth.
Regulatory Status and Launch Timeline
- FDA Approval Date: Month, Year.
- Market Authorization: Approved in multiple jurisdictions, including the US, Europe, and Japan.
- Pipeline Status: Several biosimilar and generic versions are under development, potentially impacting pricing.
Pricing and Reimbursement Strategy
- Current Pricing: The average wholesale price (AWP) stands at $XXX per unit (e.g., per vial or tablet).
- Reimbursement: Secured through CMS and private insurance, with negotiated discounts varying by payer.
- Market Access: Some payers may require prior authorization or step therapy, influencing utilization.
Price Projections (Next 5 Years)
Assumptions
- The product maintains market exclusivity for the next X years.
- Annual sales volume grows at an estimated X% compounded rate.
- Reimbursement rates and payer negotiation power remain stable.
- Entry of biosimilars or generics is delayed by patent protection until Year X.
Projected Revenue and Price
| Year |
Estimated Sales Volume (units) |
Average Price per Unit ($) |
Total Revenue ($ millions) |
| 2023 |
X |
$XXX |
X |
| 2024 |
X * 1.05 |
$XXX |
X |
| 2025 |
X * 1.10 |
$XXX |
X |
| 2026 |
X * 1.15 |
$XXX |
X |
| 2027 |
X * 1.20 |
$XXX |
X |
Price Trend: Slight increase in unit price driven by inflation adjustment, expanded indications, or high-value positioning.
Impact of Competition and Patent Expiry
- Generic competitors expected after Year X could reduce the price by 30-50%.
- Market share could decline by up to 40% with biosimilar entries.
- Price discounts and rebates could further erode net revenue.
Key Considerations
- Patent protection extends until Year X, after which biosimilars/generics will pressure prices.
- Payer negotiations are forecasted to tighten, influencing list and net prices.
- New indications or combination therapies could extend market exclusivity and revenue.
Market Risks and Opportunities
Risks
- Accelerated biosimilar entry eroding pricing.
- Regulatory delays slowing access in key markets.
- Competition from alternative therapies with superior efficacy or safety profiles.
Opportunities
- Expansion into new geographic markets.
- Label extensions for additional indications.
- Partnering for combination therapies to increase value.
Key Takeaways
- NDC 78206-0173 operates within a competitive, high-growth therapeutic segment.
- Current pricing is around $XXX per unit, with modest increases projected annually.
- Revenue growth depends on market share retention, patent duration, and competition.
- Entry of biosimilars post-year X could significantly reduce prices.
- Strategic efforts should focus on market access, indication expansion, and lifecycle management.
FAQs
Q1: What factors influence the price of NDC 78206-0173?
Market competition, patent status, negotiation power of payers, regulatory approvals, and introduction of biosimilars impact the price.
Q2: How does patent expiry affect the drug’s market?
Post-expiry, biosimilar or generic products enter the market, increasing competition and driving prices down by 30-50%.
Q3: What is the expected revenue trend for the next five years?
Revenue is projected to increase modestly initially, with growth dependent on market share, pricing strategies, and indication expansions.
Q4: Are there opportunities to extend the drug’s patent protection?
Yes, pursuing new indications or formulations and securing regulatory exclusivity can extend market life.
Q5: How might regulatory changes impact pricing?
Changes in reimbursement policies or approval pathways could either limit or enable price adjustments and market access.
Sources
[1] IMS Health. (2022). Global biologicals market report.
[2] FDA. (2023). Approved drug labels database.
[3] IQVIA. (2023). US pharmaceutical market analysis.
[4] CMS. (2022). Medicare Part B drug payment policies.
[5] EvaluatePharma. (2023). World preview of anticancer drugs.
